{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "BSO",
      "Fever",
      "IL-1\u03b2",
      "IL-6",
      "Inflammation"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "27764704",
  "DateCompleted": {
    "Year": "2018",
    "Month": "01",
    "Day": "04"
  },
  "DateRevised": {
    "Year": "2018",
    "Month": "06",
    "Day": "09"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2016",
        "Month": "10",
        "Day": "18"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1016/j.cyto.2016.10.005",
      "S1043-4666(16)30545-2"
    ],
    "Journal": {
      "ISSN": "1096-0023",
      "JournalIssue": {
        "Volume": "90",
        "PubDate": {
          "Year": "2017",
          "Month": "Feb"
        }
      },
      "Title": "Cytokine",
      "ISOAbbreviation": "Cytokine"
    },
    "ArticleTitle": "Buthionine sulfoximine, a glutathione depletor, attenuates endotoxic fever and reduces IL-1\u03b2 and IL-6 level in rats.",
    "Pagination": {
      "StartPage": "31",
      "EndPage": "37",
      "MedlinePgn": "31-37"
    },
    "Abstract": {
      "AbstractText": [
        "The aim of our study was to investigate the effect of buthionine sulfoximine (BSO) - a glutathione depletor - on a course of endotoxic fever and IL-1\u03b2 and IL-6 production.",
        "Male Wistar rats were subjected to intraperitoneal injection of lipopolysaccharide (LPS) from E. coli (50\u03bcg/kg, ip) to provoke fever. The level of spleen glutathione, plasma interleukin (IL)-1\u03b2, IL-6, and deep body temperature (Tb) were measured.",
        "The LPS administration provoked fever (the average Tb was 38.14\u00b10.05\u00b0C in NaCl/LPS-treated rats vs 37.10\u00b10.03\u00b0C in control, not-treated rats; p<0.001). We observed that LPS injection induced a decrease in spleen glutathione level (7.67\u00b10.92nM/g vs 13.27\u00b10.47nM/g in not-treated rats; p<0.001). Furthermore, the injection of LPS provoked an elevation of plasma IL-1\u03b2 and IL-6 concentration (from values below the lowest detectable standard in not-treated animals to 199.99\u00b134.89pg/mL and 7500\u00b1542.21pg/mL, respectively; p<0.001). Pretreatment with BSO enhanced glutathione decrease in LPS-treated rats (5.05\u00b10.49nM/g), and significantly affected fever (maximal Tb was 37.81\u00b10.07\u00b0C in BSO/LPS-treated rats vs 38.76\u00b10.11\u00b0C in NaCl/LPS-treated rats). BSO 4h after LPS injection decreased IL-1\u03b2 and IL-6 gene expression (about 1.5 fold, and 2 fold, respectively). In a consequence we observed a decrease in plasma IL-6 concentration (4h after LPS injection plasma IL-6 was 4167.17\u00b1956.54pg/mL in BSO/LPS-treated rats vs 7500\u00b1542.21pg/mL in NaCl/LPS-treated rats; p<0.001), and later IL-1\u03b2 (7h after LPS injection the IL-1\u03b2 concentration was not detected).",
        "Based on these data, we conclude that BSO, in addition to well-known application as an inhibitor of glutathione synthesis, is an antipyretic agent which reduces both IL-1\u03b2 and IL-6 concentration."
      ],
      "CopyrightInformation": "Copyright \u00a9 2016 Elsevier Ltd. All rights reserved."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Immunology, Nicolaus Copernicus University, Ul. Lwowska 1, 87-100 Torun, Poland. Electronic address: wrotek@umk.pl."
          }
        ],
        "LastName": "Wrotek",
        "ForeName": "Sylwia",
        "Initials": "S"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Centre for Modern Interdisciplinary Technologies, Nicolaus Copernicus University, Wilenska 4, 87-100 Torun, Poland. Electronic address: krydom@umk.pl."
          }
        ],
        "LastName": "Domagalski",
        "ForeName": "Krzysztof",
        "Initials": "K"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Immunology, Nicolaus Copernicus University, Ul. Lwowska 1, 87-100 Torun, Poland. Electronic address: tomaszj@umk.pl."
          }
        ],
        "LastName": "J\u0119drzejewski",
        "ForeName": "Tomasz",
        "Initials": "T"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Immunology, Nicolaus Copernicus University, Ul. Lwowska 1, 87-100 Torun, Poland. Electronic address: ejc.dec@gamil.com."
          }
        ],
        "LastName": "Dec",
        "ForeName": "Eliza",
        "Initials": "E"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Immunology, Nicolaus Copernicus University, Ul. Lwowska 1, 87-100 Torun, Poland. Electronic address: wkozak@umk.pl."
          }
        ],
        "LastName": "Kozak",
        "ForeName": "Wies\u0142aw",
        "Initials": "W"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, Non-U.S. Gov't"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Cytokine",
    "NlmUniqueID": "9005353",
    "ISSNLinking": "1043-4666"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antipyretics"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "IL1B protein, rat"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Interleukin-1beta"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Interleukin-6"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Lipopolysaccharides"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Sulfoxides"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "buthionine sulfoxide"
    },
    {
      "RegistryNumber": "AE28F7PNPL",
      "NameOfSubstance": "Methionine"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Animals"
    },
    {
      "QualifierName": [
        "pharmacology"
      ],
      "DescriptorName": "Antipyretics"
    },
    {
      "QualifierName": [
        "blood",
        "chemically induced",
        "drug therapy",
        "pathology"
      ],
      "DescriptorName": "Fever"
    },
    {
      "QualifierName": [
        "blood"
      ],
      "DescriptorName": "Interleukin-1beta"
    },
    {
      "QualifierName": [
        "blood"
      ],
      "DescriptorName": "Interleukin-6"
    },
    {
      "QualifierName": [
        "toxicity"
      ],
      "DescriptorName": "Lipopolysaccharides"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [
        "analogs & derivatives",
        "pharmacology"
      ],
      "DescriptorName": "Methionine"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Rats"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Rats, Wistar"
    },
    {
      "QualifierName": [
        "pharmacology"
      ],
      "DescriptorName": "Sulfoxides"
    }
  ]
}